-
Alder BioPharmaceuticals to Host Conference Call to Discuss Third Quarter 2016 Financial and Operating Results
-
Alder BioPharma (ALDR) Appoints New CFO, PAO
-
Alder BioPharmaceuticals Promotes Larry Benedict to Executive Vice President of Finance and Principal Accounting Officer
-
Alder BioPharmaceuticals Appoints Nancy L. Boman, M.D., Ph.D., Senior Vice President of Regulatory Affairs and Pharmacovigilance
-
Alder BioPharma (ALDR) Announces Presentation of Positive ALD403 Phase 2b Data in Migraine Prevention
-
Alder Presents Positive ALD403 Clinical Data at European Headache and Migraine Trust International Congress
-
Alder Announces Presentations at the European Headache and Migraine Trust International Congress Supporting Development of ALD403 for Migraine Prevention
-
Alder BioPharmaceuticals Appoints Elisabeth A. Sandoval as Chief Commercial Officer
-
Alder BioPharmaceuticals to Present at Two Upcoming September Healthcare Conferences
-
Alder BioPharmaceuticals Reports Second Quarter 2016 Financial and Operating Results
-
Alder BioPharma (ALDR) Announces Positive Top-Line Data from ALD403 Phase 2b
-
Alder Reports Positive Top-Line 24-Week Data Demonstrating Persistent Migraine Prevention in Phase 2b Study of ALD403 in Patients with Chronic Migraine
-
Alder BioPharmaceuticals to Host Conference Call to Discuss Second Quarter 2016 Financial and Operating Results
-
Alder BioPharmaceuticals Appoints Timothy M. Whitaker, M.D., Chief Medical Officer

